Neumora Therapeutics (NMRA) Non-Current Assets (2022 - 2026)

Neumora Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $443000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 76.46% year-over-year to $443000.0; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (down 82.39% YoY), and the FY2025 full-year result was $510000.0, down 82.52% from the prior year.
• Non-Current Assets for Q1 2026 stood at $443000.0, down from $510000.0 in the prior quarter.
• The five-year high for Non-Current Assets was $38.3 million in Q4 2022, with the low at $443000.0 in Q1 2026.
• Average Non-Current Assets over 5 years is $8.3 million, with a median of $3.4 million recorded in 2024.
• Year-over-year, Non-Current Assets plunged 53.2% in 2023 and tumbled 85.12% in 2025.
• Tracing NMRA's Non-Current Assets over 5 years: stood at $38.3 million in 2022, then sank by 53.2% to $17.9 million in 2023, then tumbled by 83.72% to $2.9 million in 2024, then plunged by 82.52% to $510000.0 in 2025, then declined by 13.14% to $443000.0 in 2026.
• The last three Non-Current Assets figures came in at $443000.0 (Q1 2026), $510000.0 (Q4 2025), and $751000.0 (Q3 2025), per Business Quant data.

Peer Comparison